...
首页> 外文期刊>Cancer radiotherapie: journal de la Soci閠?fran鏰ise de radiotherapie oncologique >Iodine 125 prostate brachytherapy: prognostic factors for long-term urinary, digestive and sexual toxicities
【24h】

Iodine 125 prostate brachytherapy: prognostic factors for long-term urinary, digestive and sexual toxicities

机译:碘125前列腺近距离放射疗法:长期尿,消化和性毒性的预后因素

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: For patients with good urinary function and presenting with a low risk prostate cancer, prostate brachytherapy using iodine implants represents one of the techniques of reference. This retrospective analysis investigates urinary (U), digestive (D) and sexual (S) toxicities and their prognostic factors of duration. MATERIAL AND METHODS: From August 2000 to November 2007, 176 patients presenting with prostate adenocarcinoma underwent interstitial brachytherapy. Urinary, digestive and sexual toxicities were classified according to Common toxicities criteria for adverse events, version 3.0 (CTCAE V3.0). For each toxicity (U, D, S), the number of complications U (dysuria, nicturia...), D (proctitis, diarrhea...) and S (sexual dysfunction, loss of libido, ...) was listed and analyzed according to criteria related to the patient, implant, dosimetric data and characteristics of the toxicity. Prognostic factors identified in univariate analysis (UVA) (Log Rank) were further analyzed in multivariate analysis (MVA) (Cox model). RESULTS: With a median follow-up of 26 months (1-87), 147 patients (83.5 %) presented urinary toxicities. Among them, 29.5 % (86 patients) and 2.4 % (seven patients) presented grade 2 and 3 U toxicity respectively. In UVA, urinary grade toxicity greater than or equal to 2 (p=0.037), the presence of initial U symptoms (p=0.027) and more than two urinary toxicities (p=0.00032) were recognized as prognostic factors. The number of U toxicities was the only prognostic factor in MVA (p=0.04). D toxicity accounted for 40.6 % (71 patients). Among them, 3 % (six patients) were grade 2. None were grade 3. Two factors were identified as prognostic factors either in UVA and MVA: the number of D toxicities greater than or equal to 2 (univariate analysis: p=0,00129, multivariate analysis: p=0,002) and age less than or equal to 65 years (univariate analysis: p=0,004, multivariate analysis: p=0,007). Eighty-three patients (47.4 %) presented a sexual toxicity; 26.9 % (49 patients) and 5 % (nine patients) were scored as grade 2 and 3 respectively. A number of seeds greater than 75 (p=0.032) and S grade greater than or equal to 2 (p<0.0001) were recognized as prognostic factors in UVA. S grade was the only prognostic factor in MVA (p=0.0015). CONCLUSION: The duration of U, D and S toxicity is strongly correlated with a high number of toxicities and the grade of toxicity. This analysis allows for better information given to the patient regarding the duration of the post-treatment complications.
机译:目的:对于尿功能良好且存在低风险前列腺癌的患者,使用碘植入物进行前列腺近距离放射治疗是参考技术之一。这项回顾性分析调查了尿毒(U),消化毒(D)和性(S)毒性及其持续时间的预后因素。材料与方法:自2000年8月至2007年11月,对176例前列腺腺癌患者行间质近距离放射治疗。根据3.0版不良事件的常见毒性标准(CTCAE V3.0)对尿,消化和性毒性进行了分类。对于每种毒性(U,D,S),列出了并发症(U(尿痛,中风...),D(肠炎,腹泻...)和S(性功能障碍,性欲减退...)的数量。并根据与患者,植入物,剂量学数据和毒性特征有关的标准进行分析。在多变量分析(MVA)(Cox模型)中进一步分析了在单变量分析(UVA)(对数秩)中确定的预后因素。结果:中位随访26个月(1-87),有147例患者(83.5%)出现了尿毒症。其中有29.5%(86例)和2.4%(7例)表现出2级和3U级毒性。在UVA中,尿级毒性大于或等于2(p = 0.037),最初的U症状的存在(p = 0.027)和两种以上的尿毒症(p = 0.00032)被认为是预后因素。 U毒性的数量是MVA中唯一的预后因素(p = 0.04)。 D毒性占40.6%(71例患者)。其中3%(6例患者)为2级。无3级。两个因素被确定为UVA和MVA的预后因素:D毒性数大于或等于2(单因素分析:p = 0, 00129,多变量分析:p = 0,002)和年龄小于或等于65岁(单变量分析:p = 0,004,多变量分析:p = 0,007)。八十三例患者(47.4%)表现出性毒性反应; 26.9%(49位患者)和5%(9位患者)分别被评为2级和3级。 UVA中许多大于75(p = 0.032)和S级大于或等于2(p <0.0001)的种子被认为是预后因素。 S级是MVA中唯一的预后因素(p = 0.0015)。结论:U,D和S毒性的持续时间与大量毒性和毒性等级密切相关。这种分析可以为患者提供有关治疗后并发症持续时间的更好信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号